Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - Barclays initiated coverage of Viatris with an Overweight rating and a price target of $15, indicating improving investor sentiment in the pharmaceutical sector [2] - Viatris announced a definitive agreement to sell its equity stake in Biocon Biologics Limited for a total consideration of $815 million, which includes $400 million in cash and $415 million in newly issued equity shares [3] Company Overview - Viatris Inc. is a global pharmaceutical company that offers a diverse range of medicines, including generics, branded drugs, biosimilars, OTC products, and active pharmaceutical ingredients (APIs) [4]